Sun, Dec 21, 2014, 10:36 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Lexicon Pharmaceuticals, Inc. (LXRX) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • pkornie@sbcglobal.net pkornie Nov 7, 2011 1:00 PM Flag

    Re: LEXGE.OB

    <EOM.B>

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • pkornie@sbcglobal.net pkornie Nov 13, 2011 8:01 PM Flag

      MEXICON_THEREPUTICS.OB look_at_dis.<< << 4:32p ET October 27, 2011 (Dow Jones) Gilead 3Q Profit Rises 5.1% On Sales Growth

      DOW JONES NEWSWIRES

      Gilead Sciences Inc.'s (GILD) second-quarter profit rose 5.1% as the biopharmaceutical company's antiviral products drove revenue growth.
      The drugmaker has dominated the market for HIV treatment and receives royalties from Roche Holding AG (RHHBY, ROG.VX) for Tamiflu, which Gilead created.
      Like traditional pharmaceutical companies, biotech firms have been looking to expand their offerings to boost profits and to prepare for patent expirations. Gilead has been focusing on simplifying HIV therapy through the development of a number of single-pill combination HIV treatments.
      Complera, its second single-tablet HIV treatment for patients new to therapy, won FDA approval in August. In September the company accelerated plans to seek FDA approval of its "Quad" combination HIV drug--which analysts view as a potential growth driver. In late September, European regulators issued a positive opinion on its Eviplera pill, a combination of its Truvada with Tibotec Pharmaceuticals' Edurant, which could lead to approval later this year.
      Gilead posted a profit of $741.1 million, or 95 cents a share, up from $704.9 million, or 83 cents a share, a year earlier. Excluding charges related to acquisitions, stock-based compensation expenses and other items, earnings were up at 1.02 from 90 cents.
      Revenue increased 9.5% to $2.12 billion.
      Analysts surveyed by Thomson Reuters had most recently predicted earnings of $1.01 a share on revenue of $2.11 billion.
      Operating margin fell to 47.3% from 50.5%.
      Product sales, from which the company gets the majority of its revenue, rose 11%, driven mostly by its antiviral drugs, including HIV drugs Atripla and Truvada, which were up 7% and 11%, respectively. However, royalties from Tamiflu slumped 89%.
      Shares closed Thursday up 1.5% at $42.11 amid a broad market upturn and were inactive in after-hours trading. The stock is up 16% this year.

      -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

      (END) Dow Jones Newswires
      10-27-11 1632ET
      Copyright (c) 2011 Dow Jones & Company, Inc.BT201110270181122011-10-27 20:32:00.0002K4498JEDG9LIGBS68VRSU9IDQDJNF
      >>

      Sentiment : Strong Buy

      Sentiment : Strong Buy
      >>

 
LXRX
0.8579-0.0397(-4.42%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.